Valuation: BioCryst Pharmaceuticals, Inc.

Market Cap 2.66B 2.32B 2.14B 1.98B 3.76B 253B 3.82B 25.6B 10.05B 125B 9.97B 9.76B 429B P/E 2026 *
-4x
P/E 2027 * 19.4x
Enterprise Value 2.66B 2.32B 2.14B 1.98B 3.76B 253B 3.82B 25.6B 10.05B 125B 9.97B 9.76B 429B EV / Sales 2026 *
3.96x
EV / Sales 2027 * 3.65x
Free-Float
94.36%
Yield 2026 *
-
Yield 2027 * -
07-07 RBC Capital Adjusts BioCryst Pharmaceuticals Price Target to $14 From $13, Maintains Outperform Rating MT
06-29 BioCryst scraps internal drug discovery programs, leans on partnerships to cut costs RE
06-29 BioCryst to Discontinue Internal Discovery Programs, Close Birmingham Facility by Year-End MT
06-29 BioCryst Pharmaceuticals, Inc. Discontinues Internal Discovery Programs And Closes Birmingham Research Facility CI
06-29 BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 2000 Value Benchmark CI
06-29 BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 3000E Value Benchmark CI
06-29 BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 3000 Value Benchmark CI
06-29 BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell Small Cap Comp Value Benchmark CI
06-29 BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 2500 Value Benchmark CI
06-12 BioCryst Pharmaceuticals' New Clinical Data Demonstrated Reduced Hereditary Angioedema Attacks With Orladeyo Treatment MT
06-12 BioCryst Pharmaceuticals Presents New Clinical Data and Real-World Evidence for HAE Portfolio at the European Academy of Allergy and Clinical Immunology Annual Meeting CI
05-27 BioCryst Pharmaceuticals Presents New HAE Data From ORLADEYO And Navenibart At The European Academy Of Allergy And Clinical Immunology Annual Meeting CI
05-13 BioCryst Pharmaceuticals, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 01:40 PM
1 day-2.52%
1 week+6.20%
Current month+4.50%
1 month+27.59%
3 months+9.31%
6 months+41.22%
Current year+33.97%
1 week 9.71
Extreme 9.71
11.22
1 month 8.45
Extreme 8.45
11.22
Current year 6.23
Extreme 6.23
11.22
1 year 6
Extreme 6
11.22
3 years 4.03
Extreme 4.03
11.31
5 years 4.03
Extreme 4.03
19.99
10 years 1.38
Extreme 1.38
19.99
Manager TitleAgeSince
Chief Executive Officer 55 01/01/2026
Director of Finance/CFO 47 07/07/2025
Chief Tech/Sci/R&D Officer 51 06/04/2026
Director TitleAgeSince
Director/Board Member 65 01/01/2007
Director/Board Member 64 03/12/2018
Director/Board Member 55 01/01/2026
Date Insider Type Main position Quantity % Market Cap.
06-11Free

Director

48,834 0.0192%
06-11Free

Chairman

48,834 0.0192%
06-11Free

Director

48,834 0.0192%
Change 5-day change 1-year change 3-year change Capi.($)
-2.52%+6.20%+17.68%+41.79% 2.66B
-4.14%-8.06%+57.35%+117.24% 54.63B
+1.84%-0.66%+75.79%+93.87% 54.88B
-2.24%+3.59%+19.60%+466.72% 25.06B
-1.60%-6.21%-19.69%-14.84% 23.14B
+2.43%+1.06%+47.70%-0.11% 19.88B
-3.19%0.00%+33.99%-26.87% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
-1.05%+1.16%+25.08%+196.28% 14.2B
+8.74%+3.51%+53.81% - 15.36B
Average -0.86%+0.37%+50.64%+136.81% 24.39B
Weighted average by Cap. -0.93%-1.37%+54.64%+136.67%

Financials

2026 *2027 *
Net sales 671M 587M 541M 500M 949M 64B 965M 6.47B 2.54B 31.53B 2.52B 2.46B 108B 727M 636M 587M 542M 1.03B 69.36B 1.05B 7.01B 2.75B 34.17B 2.73B 2.67B 117B
Net income -645M -564M -520M -480M -911M -61.47B -927M -6.21B -2.44B -30.28B -2.42B -2.37B -104B 144M 126M 116M 107M 203M 13.69B 206M 1.38B 543M 6.74B 539M 527M 23.19B
Net Debt - -
Logo BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of HAE attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX17725, navenibart, Avoralstat, STAR-0310, RAPIACTA (peramivir injection) and PERAMIFLU (peramivir injection). The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Peramivir injection is also approved in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA), and Korea (PERAMIFLU). It has also obtained an early-stage program for atopic dermatitis (AD), STAR0310.
Employees
435
Date Price Change Volume
10/07/26 US$10.45 -2.52% 3,359,350
09/07/26 US$10.72 -3.51% 3,982,332
08/07/26 US$11.11 +1.09% 7,429,410
07/07/26 US$10.99 +8.06% 10,280,196
06/07/26 US$10.17 +3.35% 4,380,034
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
10.45USD
Average target price
21.90USD
Spread / Average Target
+109.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BCRX Stock